Michiel Sedelaar

Dr. Michiel Sedelaar

dep urology Radboudumc The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LKLejla Koco
Lejla Koco
HWHarm H.A. Weekenstroo
Harm H.A. Weekenstroo
DLDoenja M. J. Lambregts
Doenja M. J. Lambregts
MSMichiel Sedelaar
Michiel Sedelaar
MPMathias Prokop
Mathias Prokop
RMRitse M. Mann
Ritse M. Mann
Objective: The aim of our systematic review is to identify the effects of multidisciplinary team meetings (MDTM) for lung, breast, colorectal and prostate cancer. Methods: Our systematic review, performed following PRISMA guidelines, included studies examining the impact of MDTMs on treatment decisions, patient and process outcomes. Electronic databases PUBMED, EMBASE, Cochrane Library and Web of Science were searched for articles published between 2000 and 2020. Risk of bias and level of evidence were assessed using the ROBINS-I tool and GRADE scale. Results: 41 of 13,246 articles were selected, evaluating colorectal (21), lung (10), prostate (6) and breast (4) cancer. Results showed that management plans were changed in 1.6–58% of cases after MDTMs. Studies reported a significant impact of MDTMs on surgery type, and a reduction of overall performed surgery after MDTM. Results also suggest that CT and MRI imaging significantly increased after MDTM implementation. Survival rate increased significantly with MDTM discussions according to twelve studies, yet three studies did not show significant differences. Conclusions: Despite heterogeneous data, MDTMs showed a significant impact on management plans, process outcomes and patient outcomes. To further explore the impact of MDTMs on the quality of healthcare, high-quality research is needed.

22 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SKSosse Klarenbeek
Sosse Klarenbeek
HWHarm H.A. Weekenstroo
Harm H.A. Weekenstroo
MSMichiel Sedelaar
Michiel Sedelaar
JFJurgen Fütterer
Jurgen Fütterer
MPMathias Prokop
Mathias Prokop
MTMarcia Tummers
Marcia Tummers
Background: To deal with complexity in cancer care, computerized clinical decision support systems (CDSSs) are developed to support quality of care and improve decision-making. We performed a systematic review to explore the value of CDSSs using automated clinical guidelines, Artificial Intelligence, datamining or statistical methods (higher level CDSSs) on the quality of care in oncology. Materials and Methods: The search strategy combined synonyms for ‘CDSS’ and ‘cancer.’ Pubmed, Embase, The Cochrane Library, Institute of Electrical and Electronics Engineers, Association of Computing Machinery digital library and Web of Science were systematically searched from January 2000 to December 2019. Included studies evaluated the impact of higher level CDSSs on process outcomes, guideline adherence and clinical outcomes. Results: 11,397 studies were selected for screening, after which 61 full-text articles were assessed for eligibility. Finally, nine studies were included in the final analysis with a total population size of 7985 patients. Types of cancer included breast cancer (63.1%), lung cancer (27.8%), prostate cancer (4.1%), colorectal cancer (3.1%) and other cancer types (1.9%). The included studies demonstrated significant improvements of higher level CDSSs on process outcomes and guideline adherence across diverse settings in oncology. No significant differences were reported for clinical outcomes. Conclusion: Higher level CDSSs seem to improve process outcomes and guidelines adherence but not clinical outcomes. It should be noticed that the included studies primarily focused on breast and lung cancer. To further explore the impact of higher level CDSSs on quality of care, high-quality research is required.

1 May 2024 in Radiology
Verified
Journal Article
Closed access
BPBastiaan Privé
Bastiaan Privé
BIBas Israël
Bas Israël
MJMarcel J. R. Janssen
Marcel J. R. Janssen
MLMarloes M. G. van der Leest
Marloes M. G. van der Leest
MRMaarten de Rooij
Maarten de Rooij
JNJames Nagarajah
James Nagarajah
Fluorine 18 prostate-specific membrane antigen 1007 PET/CT showed good sensitivity and moderate specificity for the detection of clinically significant prostate cancer, effectively ruling this out in 93% of participants with Prostate Imaging Reporting and Data System category 3 lesions.

18 December 2022 in BJU International
Verified
Journal Article
Closed access
DBDiederik Baas
Diederik Baas
WVWillem Vreuls
Willem Vreuls
MSMichiel Sedelaar
Michiel Sedelaar
HVHenricus J.E.J. Vrijhof
Henricus J.E.J. Vrijhof
RHRobert J. Hoekstra
Robert J. Hoekstra
DSDiederik Meindert Somford
Diederik Meindert Somford

1 July 2022 in Journal of Urology
Verified
Journal Article
Open access
STSofie C. M. Tops
Sofie C. M. Tops
JGJustin G. A. Grootenhuis
Justin G. A. Grootenhuis
ADAnouk M. Derksen
Anouk M. Derksen
FGFederica Giardina
Federica Giardina
EKEva Kolwijck
Eva Kolwijck
MSMichiel Sedelaar
Michiel Sedelaar
Purpose:To compare infectious complication rates between different prostate biopsy techniques with various number of biopsy cores.Materials and Methods:In this retrospective study, all patients fro...

3 April 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EKE. Kolwijck
E. Kolwijck
ASA. E. M. Seegers
A. E. M. Seegers
STS. C. M. Tops
S. C. M. Tops
AHAntoine G. van der Heijden
Antoine G. van der Heijden
MSMichiel Sedelaar
Michiel Sedelaar
JOJaap ten Oever
Jaap ten Oever
Post-operative infections are frequent after radical cystectomy with urinary diversion surgery (UDS). Reduction of post-operative infections necessitates appropriate peri-operative antimicrobial prophylaxis targeting causative bacteria. We assessed the incidence and microbiology of infections in the 30-day post-operative period after UDS and investigated effectiveness of the currently used peri-operative antibacterial prophylaxis. Retrospective cohort study of all patients undergoing UDS in a tertiary university medical center from January 2014 until September 2016. Antibiotic prophylaxis consisted of cefazolin plus metronidazol according to the Dutch national guideline. Primary outcome was the incidence of post-operative infections within 30 days. Risk factors for post-operative infections and antimicrobial susceptibility profiles of cultured bacteria were also assessed. 147 patients were included. 69 patients (46.9%) had 82 post-operative infections, 27 of which were patients with bacteremia (18.4%). Highest incidence of infections was on day 4–5 and on day 8–10 postoperatively. The second peak was associated with ureteral stent removal. 4.8% of 147 study patients developed bacteremia 24 h after stent removal, which counted for 25.9% of all bacteremia episodes found in this study. Enterobacteriaceae were cultured in 67.9% of blood cultures and were only highly susceptible to ciprofloxacine, piperacillin-tazobactam (90%), meropenem and gentamicin (100%). Multivariate logistic regression analysis showed orthotopic Hautmann neobladder to be associated with increased infections complications: odds ratio 4.1 (95% confidence interval 1.6–10.5), p = 0.03. The incidence of infections after radical cystectomy is high and particularly ureteral stent removal was associated with both bacteremia and complicated urinary tract infections. Based on the results of this study, antibiotic prophylaxis might need to be broadened for patients undergoing radical cystectomy. Further research is required to investigate whether current guidelines need to be altered concerning administration of antibiotic prophylaxis just before stent removal.